Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
ShangPharma Innovation
AddedFeb 13, 2024
UpdatedJun 28, 2026
ShangPharma Innovation

ShangPharma Innovation

Operating

ShangPharma Innovation: A global venture capital firm incubating and investing in biomedical R&D and therapeutics.

Location
San Francisco, CA, US
Founded
2016
Firm
Compare
Portfolio
Employees
Website

ShangPharma Innovation is a global venture capital firm specializing in biomedical R&D technologies and therapeutics. The firm typically invests in Series A rounds, supporting early-stage companies with innovative solutions in the healthcare sector. ShangPharma's investment focus spans across various geographies, aiming to foster advancements that can significantly impact patients' lives.

Notable portfolio companies include Abcuro, Blue Oak Pharmaceuticals, Mediar Therapeutics, Pykus Therapeutics, Quartet Medicine, Skyhawk Therapeutics, and Valitor. ShangPharma Innovation collaborates with prestigious institutions like MD Anderson Cancer Center, highlighting its commitment to cutting-edge research. The firm's investment philosophy centers on nurturing groundbreaking innovations, providing not only capital but also strategic support and industry expertise to its portfolio companies.

ShangPharma Innovation - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments8
Current Portfolio Count8
Total Portfolio Exits0

Top Investment Stages

Series A6 (75.0%)
Series Unknown2 (25.0%)

Stage Mix

Series A 75%Series Unknown 25%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Mediar Therapeutics logo

Mediar Therapeutics

Pykus Therapeutics logo

Pykus Therapeutics

Blue Oak Pharmaceuticals logo

Blue Oak Pharmaceuticals

Abcuro logo

Abcuro

Valitor logo

Valitor

Skyhawk Therapeutics logo

Skyhawk Therapeutics

Evrys Bio logo

Evrys Bio

Quartet Medicine logo

Quartet Medicine

ShangPharma Innovation - Classification

Also Known As
  • ShangPharma Innovation Inc.
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 7300Business Services
Show 2 more industry codes
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541000Professional, Scientific, and Technical Services